ATE437859T1 - 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten - Google Patents
6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonistenInfo
- Publication number
- ATE437859T1 ATE437859T1 AT06802904T AT06802904T ATE437859T1 AT E437859 T1 ATE437859 T1 AT E437859T1 AT 06802904 T AT06802904 T AT 06802904T AT 06802904 T AT06802904 T AT 06802904T AT E437859 T1 ATE437859 T1 AT E437859T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- sub
- substituted
- tetrahydro
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71358405P | 2005-09-01 | 2005-09-01 | |
PCT/US2006/034430 WO2007028131A1 (en) | 2005-09-01 | 2006-09-01 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE437859T1 true ATE437859T1 (de) | 2009-08-15 |
Family
ID=37499390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06802904T ATE437859T1 (de) | 2005-09-01 | 2006-09-01 | 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten |
Country Status (17)
Country | Link |
---|---|
US (1) | US8420631B2 (de) |
EP (1) | EP1926712B1 (de) |
JP (1) | JP5237810B2 (de) |
CN (1) | CN101253153A (de) |
AT (1) | ATE437859T1 (de) |
AU (1) | AU2006287160B2 (de) |
BR (1) | BRPI0615033A2 (de) |
CA (1) | CA2619287C (de) |
CY (1) | CY1110486T1 (de) |
DE (1) | DE602006008155D1 (de) |
DK (1) | DK1926712T3 (de) |
ES (1) | ES2328408T3 (de) |
MX (1) | MX2008002180A (de) |
PL (1) | PL1926712T3 (de) |
PT (1) | PT1926712E (de) |
SI (1) | SI1926712T1 (de) |
WO (1) | WO2007028131A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7981882B2 (en) * | 2005-09-01 | 2011-07-19 | Eli Lilly And Company | 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists |
EP1924560B1 (de) * | 2005-09-01 | 2009-08-05 | Eli Lilly And Company | 6-substituierte- 2,3,4,5-tetrahydro-1h-benzo[d]azepine als 5-ht2c-rezeptoragonisten |
JP5155864B2 (ja) * | 2005-09-01 | 2013-03-06 | イーライ リリー アンド カンパニー | 5−HT2C受容体アゴニストとしての6−アリールアルキルアミノ−2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン |
WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
US7897595B2 (en) | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
WO2009063992A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
CN101684096A (zh) * | 2008-09-23 | 2010-03-31 | 中国科学院上海药物研究所 | 一类新型苯并氮杂卓类化合物及其制备方法和用途 |
BRPI1011502A2 (pt) | 2009-06-15 | 2016-03-22 | Takeda Pharmaceutical | composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto. |
KR20130138768A (ko) * | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 5-ht2c 아고니스트의 신속-용해성 투여 형태 |
EP2611782A1 (de) * | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Lorcaserin-salze mit optisch aktiven säuren |
US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
EP2611433A2 (de) * | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Nicht-hygroskopische salze aus 5-ht2c-agonisten |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4265890A (en) | 1978-07-07 | 1981-05-05 | Smithkline Corporation | 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines |
EP0285287A3 (de) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | Verwendung von 3-Benzazepinen zur Behandlung von gastrointestinalen Mobilitätsstörungen |
US4985352A (en) | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
US5639748A (en) * | 1991-08-05 | 1997-06-17 | Smithkline Beecham Corporation | 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity |
GB9116824D0 (en) * | 1991-08-05 | 1991-09-18 | Smithkline Beecham Corp | Chemical compounds |
DE69224618T2 (de) * | 1991-09-11 | 1998-07-16 | Canon Kk | Säuberungsglied für einen tintenstrahlkopf und mit solchem säuberungsglied ausgestattetes tintenstrahlgerät |
GB9119467D0 (en) | 1991-09-12 | 1991-10-23 | Smithkline Beecham Corp | Chemical compounds |
US5698766A (en) | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
JP2002371059A (ja) * | 2000-05-16 | 2002-12-26 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
EP1213017A3 (de) | 2000-12-05 | 2003-11-12 | Akzo Nobel N.V. | Verwendung von einem 5-HT2C Rezeptor Agonist zur Behandlung von Hitzewallungen |
WO2002074746A1 (fr) * | 2001-03-16 | 2002-09-26 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de benzazepine |
JP2005522408A (ja) | 2001-07-13 | 2005-07-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 5−HT受容体リガントとしてのヘキサヒドロアゼピノ(4,5−g)インドールおよびインドリン |
MXPA04005151A (es) * | 2001-11-28 | 2004-08-11 | Upjohn Co | Compuestos terapeuticos. |
US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
CN101792417A (zh) * | 2003-06-17 | 2010-08-04 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
MXPA05013364A (es) | 2003-06-17 | 2006-03-17 | Arena Pharm Inc | Procedimiento para preparar 3-benzazepinas. |
TW200510324A (en) * | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
WO2005042490A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
WO2005082859A1 (en) * | 2004-02-25 | 2005-09-09 | Eli Lilly And Company | 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
SI1838677T1 (sl) | 2004-12-21 | 2010-01-29 | Arena Pharm Inc | Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida |
EA015012B1 (ru) | 2004-12-23 | 2011-04-29 | Арена Фармасьютикалз, Инк. | Композиция, содержащая фентермин и избирательный агонист рецептора 5ht, и ее применение |
US7981882B2 (en) * | 2005-09-01 | 2011-07-19 | Eli Lilly And Company | 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists |
JP5155864B2 (ja) * | 2005-09-01 | 2013-03-06 | イーライ リリー アンド カンパニー | 5−HT2C受容体アゴニストとしての6−アリールアルキルアミノ−2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン |
EP1924560B1 (de) * | 2005-09-01 | 2009-08-05 | Eli Lilly And Company | 6-substituierte- 2,3,4,5-tetrahydro-1h-benzo[d]azepine als 5-ht2c-rezeptoragonisten |
-
2006
- 2006-09-01 PT PT06802904T patent/PT1926712E/pt unknown
- 2006-09-01 EP EP06802904A patent/EP1926712B1/de not_active Not-in-force
- 2006-09-01 BR BRPI0615033-0A patent/BRPI0615033A2/pt not_active IP Right Cessation
- 2006-09-01 PL PL06802904T patent/PL1926712T3/pl unknown
- 2006-09-01 MX MX2008002180A patent/MX2008002180A/es active IP Right Grant
- 2006-09-01 AT AT06802904T patent/ATE437859T1/de active
- 2006-09-01 DE DE602006008155T patent/DE602006008155D1/de active Active
- 2006-09-01 JP JP2008529360A patent/JP5237810B2/ja not_active Expired - Fee Related
- 2006-09-01 US US11/995,344 patent/US8420631B2/en not_active Expired - Fee Related
- 2006-09-01 ES ES06802904T patent/ES2328408T3/es active Active
- 2006-09-01 AU AU2006287160A patent/AU2006287160B2/en not_active Ceased
- 2006-09-01 WO PCT/US2006/034430 patent/WO2007028131A1/en active Application Filing
- 2006-09-01 CN CNA2006800318925A patent/CN101253153A/zh active Pending
- 2006-09-01 CA CA2619287A patent/CA2619287C/en not_active Expired - Fee Related
- 2006-09-01 DK DK06802904T patent/DK1926712T3/da active
- 2006-09-01 SI SI200630454T patent/SI1926712T1/sl unknown
-
2009
- 2009-09-02 CY CY20091100923T patent/CY1110486T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MX2008002180A (es) | 2008-04-22 |
CA2619287C (en) | 2013-10-22 |
BRPI0615033A2 (pt) | 2011-04-26 |
US20080207897A1 (en) | 2008-08-28 |
DE602006008155D1 (de) | 2009-09-10 |
PL1926712T3 (pl) | 2009-12-31 |
ES2328408T3 (es) | 2009-11-12 |
DK1926712T3 (da) | 2009-11-09 |
AU2006287160A1 (en) | 2007-03-08 |
CY1110486T1 (el) | 2015-04-29 |
JP5237810B2 (ja) | 2013-07-17 |
EP1926712B1 (de) | 2009-07-29 |
CN101253153A (zh) | 2008-08-27 |
WO2007028131A1 (en) | 2007-03-08 |
JP2009507037A (ja) | 2009-02-19 |
EP1926712A1 (de) | 2008-06-04 |
CA2619287A1 (en) | 2007-03-08 |
US8420631B2 (en) | 2013-04-16 |
AU2006287160B2 (en) | 2012-04-05 |
SI1926712T1 (sl) | 2010-01-29 |
PT1926712E (pt) | 2009-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE437859T1 (de) | 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten | |
ECSP066788A (es) | 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUBSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C | |
WO2007028083A3 (en) | 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists | |
DE602006008323D1 (de) | 6-substituierte- 2,3,4,5-tetrahydro-1h-benzoädüazepine als 5-ht2c-rezeptoragonisten | |
WO2007028132A3 (en) | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | |
AR045229A1 (es) | 6-(2,2,2-trifluoroetilamino)-7 cloro-2,3,4,5- tetrahidro-1h- benzo [d] azepina como agonista del receptor 5- ht2c | |
ATE435206T1 (de) | Heteroarylsulfonylstilbene als 5-ht2a- antagonisten | |
BR0115436A (pt) | Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina | |
MX2007013021A (es) | Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c. | |
EP1993560A4 (de) | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht | |
MX2007007220A (es) | Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos. | |
ECSP088094A (es) | Antagonistas y agonistas de piperazin-piperidina del receptor 5-ht1a | |
MX2007012883A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
EA200801738A1 (ru) | Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа | |
CY1110443T1 (el) | Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων | |
HK1129226A1 (de) | ||
ATE478052T1 (de) | 1,3,4-substituierte pyrazole als 5-ht rezeptor- antagonisten zur behandlung von psychosen und neurologischen störungen | |
DK1381614T3 (da) | Antidepressive azaheterocyclylmethylderivater af 2,3-dihydro-1,4-dioxino[2,3-f]quinoxalin | |
ATE498619T1 (de) | Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren | |
ATE359269T1 (de) | 4-arylsulphonylpiperidin-derivate als 5-ht2a - rezeptor antagonisten | |
ATE534638T1 (de) | Piperazin-derivate | |
CY1115160T1 (el) | 6-υποκατεστημενες 2,3,4,5-τετραϋδρο-1η-βενζο [d]αζεπινες ως αγωνιστες υποδοχεα 5-ht2c | |
DOP2004000972A (es) | 6-(2,2,2-trifluoroetilamino)-7-cloro-2,3,4,5-tetrahidro 1h-benzo[d] azepina como agonista del receptor 5-ht2c | |
DE602004012318D1 (de) | Crf-rezeptorantagonisten und diese betreffende verfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1926712 Country of ref document: EP |